These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 21078841)

  • 21. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
    Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
    Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
    Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
    Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
    Schwope DM; Karschner EL; Gorelick DA; Huestis MA
    Clin Chem; 2011 Oct; 57(10):1406-14. PubMed ID: 21836075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.
    Cherniakov I; Izgelov D; Barasch D; Davidson E; Domb AJ; Hoffman A
    J Control Release; 2017 Nov; 266():1-7. PubMed ID: 28890215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of tetrahydrocannabinol:cannabidiol oromucosal spray on cognition: a systematic review.
    Motaghi E; Ghasemi-Pirbaluti M; Rashidi M; Alasvand M; Di Ciano P; Bozorgi H
    Eur J Clin Pharmacol; 2023 Mar; 79(3):371-381. PubMed ID: 36700997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
    Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
    J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
    Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
    Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
    Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
    Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
    Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
    Schwilke EW; Schwope DM; Karschner EL; Lowe RH; Darwin WD; Kelly DL; Goodwin RS; Gorelick DA; Huestis MA
    Clin Chem; 2009 Dec; 55(12):2180-9. PubMed ID: 19833841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
    Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
    Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
    J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomised controlled trial of vaporised Δ
    Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
    Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.